MedTrace Logo

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

NCT00003394 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2013-06-24

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy consisting of estramustine, paclitaxel, and carboplatin in treating patients with advanced prostate cancer.

Conditions

Interventions

DRUG

carboplatin

DRUG

endocrine-modulating drug therapy

DRUG

estramustine phosphate sodium

DRUG

goserelin acetate

DRUG

leuprolide acetate

DRUG

paclitaxel

Sponsors & Collaborators

Principal Investigators

  • William K. Kelly, DO · Memorial Sloan Kettering Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-04-30
Primary Completion
2003-04-30
Completion
2003-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003394 on ClinicalTrials.gov